News Image

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Mar 6, 2025

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)

Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025

Read more at globenewswire.com

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (7/28/2025, 8:09:08 PM)

After market: 3.79 0 (0%)

3.79

-0.11 (-2.82%)



Find more stocks in the Stock Screener

Follow ChartMill for more